Neutrolin Versus Heparin for Locking Hemodialysis Catheters
Primary Purpose
Hemodialysis Catheter Infection, Catheter Thrombosis
Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Heparin
Neutrolin
Sponsored by
About this trial
This is an interventional treatment trial for Hemodialysis Catheter Infection
Eligibility Criteria
Inclusion Criteria:
- New hemodialysis catheter
- Subject who will need chronic hemodialysis at least twice/week
- Subject likely to require for at least 120 days
- Subject or relative is likely to understand the nature of the study and sign the consent
- Age 18 years and older
Exclusion Criteria:
- Subject with unstable malignancy
- Subject with liver cirrhosis with encephalopathy
- Subject know to have allergy to heparin, citrate or traoulidine
- Documented history of arterial thrombosis or known to have hypercoagulable state
- Subjects with active skin infections and ulcers
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
Heparin group
Neotrolin Group
Arm Description
Outcomes
Primary Outcome Measures
Proportion of catheter related blood stream infections (CRBSI per 1000 CVC days)
Rate of hemodialysis catheter in each study arm
Secondary Outcome Measures
Proportion of hemodialysis catheters with poor flow due to thrombosis
Rate of catheter dysfunction in each group
Full Information
NCT ID
NCT03425448
First Posted
January 25, 2018
Last Updated
March 4, 2019
Sponsor
King Abdullah International Medical Research Center
1. Study Identification
Unique Protocol Identification Number
NCT03425448
Brief Title
Neutrolin Versus Heparin for Locking Hemodialysis Catheters
Official Title
Neutrolin Versus Heparin for Locking Hemodialysis Catheters: A Multi-center, Double-Blind, Randomized Controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
March 2019
Overall Recruitment Status
Unknown status
Study Start Date
April 4, 2019 (Anticipated)
Primary Completion Date
October 4, 2020 (Anticipated)
Study Completion Date
April 4, 2021 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
King Abdullah International Medical Research Center
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Hemodialysis catheter related bacterial infections represent a major cause of mortality and morbidity in the hemodialysis population. Several locking agents had been tried with variable degree of success but not without side effects.
Neutrolin catheter locking agent comprises of heparin,citrate and trauolidine that had been studied in a prospective study in Germany, and it demonstrated a very good result in terms of reducing the catheter related infections and thrombosis.
This study is a multi-center, double-blind RCT comparing the hemodialysis catheter locking solution Neutrolin with heparin in reducing the rate of catheter related bacterial infection and thrombosis.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hemodialysis Catheter Infection, Catheter Thrombosis
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Sequential Assignment
Model Description
Multi-center, double-blind, randomized controlled trial
Masking
None (Open Label)
Allocation
Randomized
Enrollment
192 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Heparin group
Arm Type
Active Comparator
Arm Title
Neotrolin Group
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
Heparin
Intervention Description
Heparin hemodialysis catheter lock solution
Intervention Type
Device
Intervention Name(s)
Neutrolin
Intervention Description
Neutrolin hemodialysis catheter lock
Primary Outcome Measure Information:
Title
Proportion of catheter related blood stream infections (CRBSI per 1000 CVC days)
Description
Rate of hemodialysis catheter in each study arm
Time Frame
18 month
Secondary Outcome Measure Information:
Title
Proportion of hemodialysis catheters with poor flow due to thrombosis
Description
Rate of catheter dysfunction in each group
Time Frame
18 month
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
New hemodialysis catheter
Subject who will need chronic hemodialysis at least twice/week
Subject likely to require for at least 120 days
Subject or relative is likely to understand the nature of the study and sign the consent
Age 18 years and older
Exclusion Criteria:
Subject with unstable malignancy
Subject with liver cirrhosis with encephalopathy
Subject know to have allergy to heparin, citrate or traoulidine
Documented history of arterial thrombosis or known to have hypercoagulable state
Subjects with active skin infections and ulcers
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Neutrolin Versus Heparin for Locking Hemodialysis Catheters
We'll reach out to this number within 24 hrs